![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Object Symbol | Species | Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | TBC1D30 | Human | (1->4)-beta-D-glucan | multiple interactions | ISO | Tbc1d30 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of TBC1D30 mRNA | CTD | PMID:36331819 | TBC1D30 | Human | 1,2-dichloroethane | decreases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | ethylene dichloride results in decreased expression of TBC1D30 mRNA | CTD | PMID:28189721 and PMID:28960355 | TBC1D30 | Human | 17alpha-ethynylestradiol | increases expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | Ethinyl Estradiol results in increased expression of TBC1D30 mRNA | CTD | PMID:29097150 | TBC1D30 | Human | 17beta-estradiol | multiple interactions | EXP | | 6480464 | [Estradiol co-treated with TGFB1 protein] results in decreased expression of TBC1D30 mRNA | CTD | PMID:30165855 | TBC1D30 | Human | 17beta-estradiol | increases expression | EXP | | 6480464 | Estradiol results in increased expression of TBC1D30 mRNA | CTD | PMID:31614463 | TBC1D30 | Human | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | EXP | | 6480464 | Dihydrotestosterone results in increased expression of TBC1D30 mRNA | CTD | PMID:29581250 | TBC1D30 | Human | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of TBC1D30 mRNA | CTD | PMID:22298810 | TBC1D30 | Human | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | Tetrachlorodibenzodioxin results in increased expression of TBC1D30 mRNA | CTD | PMID:33387578 | TBC1D30 | Human | 3,3',5,5'-tetrabromobisphenol A | decreases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | tetrabromobisphenol A results in decreased expression of TBC1D30 mRNA | CTD | PMID:25172293 | TBC1D30 | Human | 4,4'-sulfonyldiphenol | decreases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | bisphenol S results in decreased expression of TBC1D30 mRNA | CTD | PMID:33297965 | TBC1D30 | Human | amphetamine | decreases expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | Amphetamine results in decreased expression of TBC1D30 mRNA | CTD | PMID:30779732 | TBC1D30 | Human | aristolochic acid A | decreases expression | EXP | | 6480464 | aristolochic acid I results in decreased expression of TBC1D30 mRNA | CTD | PMID:33212167 | TBC1D30 | Human | benzo[b]fluoranthene | increases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | benzo(b)fluoranthene results in increased expression of TBC1D30 mRNA | CTD | PMID:26377693 | TBC1D30 | Human | bis(2-ethylhexyl) phthalate | decreases expression | EXP | | 6480464 | Diethylhexyl Phthalate results in decreased expression of TBC1D30 mRNA | CTD | PMID:31163220 | TBC1D30 | Human | bisphenol A | affects expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | bisphenol A affects the expression of TBC1D30 mRNA | CTD | PMID:25181051 | TBC1D30 | Human | bisphenol A | decreases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | bisphenol A results in decreased expression of TBC1D30 mRNA | CTD | PMID:32156529 | TBC1D30 | Human | bisphenol A | increases expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | bisphenol A results in increased expression of TBC1D30 mRNA | CTD | PMID:30816183 | TBC1D30 | Human | bisphenol F | decreases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | bisphenol F results in decreased expression of TBC1D30 mRNA | CTD | PMID:30951980 | TBC1D30 | Human | caffeine | affects phosphorylation | EXP | | 6480464 | Caffeine affects the phosphorylation of TBC1D30 protein | CTD | PMID:35688186 | TBC1D30 | Human | carbamazepine | affects expression | EXP | | 6480464 | Carbamazepine affects the expression of TBC1D30 mRNA | CTD | PMID:25979313 | TBC1D30 | Human | carbon nanotube | decreases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | Nanotubes more ... | CTD | PMID:25554681 and PMID:25620056 | TBC1D30 | Human | chlorpyrifos | increases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | Chlorpyrifos results in increased expression of TBC1D30 mRNA | CTD | PMID:37019170 | TBC1D30 | Human | copper atom | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in decreased expression of TBC1D30 mRNA | CTD | PMID:20971185 | TBC1D30 | Human | copper(0) | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in decreased expression of TBC1D30 mRNA | CTD | PMID:20971185 | TBC1D30 | Human | dibenz[a,h]anthracene | increases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | 1 more ... | CTD | PMID:26377693 | TBC1D30 | Human | Dibutyl phosphate | affects expression | EXP | | 6480464 | di-n-butylphosphoric acid affects the expression of TBC1D30 mRNA | CTD | PMID:37042841 | TBC1D30 | Human | dioxygen | multiple interactions | ISO | Tbc1d30 (Mus musculus) | 6480464 | [NFE2L2 protein affects the susceptibility to Oxygen] which affects the expression of TBC1D30 mRNA | CTD | PMID:30529165 | TBC1D30 | Human | dorsomorphin | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | TBC1D30 | Human | elemental selenium | decreases expression | EXP | | 6480464 | Selenium results in decreased expression of TBC1D30 mRNA | CTD | PMID:19244175 | TBC1D30 | Human | entinostat | decreases expression | EXP | | 6480464 | entinostat results in decreased expression of TBC1D30 mRNA | CTD | PMID:26272509 | TBC1D30 | Human | entinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA | CTD | PMID:27188386 | TBC1D30 | Human | fenvalerate | increases expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | fenvalerate results in increased expression of TBC1D30 mRNA | CTD | PMID:30307764 | TBC1D30 | Human | gentamycin | decreases expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | Gentamicins results in decreased expression of TBC1D30 mRNA | CTD | PMID:33387578 | TBC1D30 | Human | indole-3-methanol | affects expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | indole-3-carbinol affects the expression of TBC1D30 mRNA | CTD | PMID:21396975 | TBC1D30 | Human | inulin | multiple interactions | ISO | Tbc1d30 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Inulin] results in decreased expression of TBC1D30 mRNA | CTD | PMID:36331819 | TBC1D30 | Human | methylmercury chloride | decreases expression | EXP | | 6480464 | methylmercuric chloride results in decreased expression of TBC1D30 mRNA | CTD | PMID:23179753 more ... | TBC1D30 | Human | ozone | multiple interactions | ISO | Tbc1d30 (Mus musculus) | 6480464 | [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of TBC1D30 mRNA and [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of TBC1D30 mRNA | CTD | PMID:34911549 | TBC1D30 | Human | panobinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA | CTD | PMID:27188386 | TBC1D30 | Human | panobinostat | decreases expression | EXP | | 6480464 | panobinostat results in decreased expression of TBC1D30 mRNA | CTD | PMID:26272509 | TBC1D30 | Human | paracetamol | increases expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | Acetaminophen results in increased expression of TBC1D30 mRNA | CTD | PMID:33387578 | TBC1D30 | Human | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Tbc1d30 (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of TBC1D30 mRNA more ... | CTD | PMID:36331819 | TBC1D30 | Human | phenylmercury acetate | decreases expression | EXP | | 6480464 | Phenylmercuric Acetate results in decreased expression of TBC1D30 mRNA | CTD | PMID:26272509 | TBC1D30 | Human | phenylmercury acetate | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA | CTD | PMID:27188386 | TBC1D30 | Human | pirinixic acid | increases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | pirinixic acid results in increased expression of TBC1D30 mRNA | CTD | PMID:23811191 | TBC1D30 | Human | SB 431542 | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | TBC1D30 | Human | selenium atom | decreases expression | EXP | | 6480464 | Selenium results in decreased expression of TBC1D30 mRNA | CTD | PMID:19244175 | TBC1D30 | Human | sulforaphane | decreases expression | EXP | | 6480464 | sulforaphane results in decreased expression of TBC1D30 mRNA | CTD | PMID:26833863 | TBC1D30 | Human | sunitinib | increases expression | EXP | | 6480464 | Sunitinib results in increased expression of TBC1D30 mRNA | CTD | PMID:31533062 | TBC1D30 | Human | thioacetamide | increases expression | ISO | Tbc1d30 (Rattus norvegicus) | 6480464 | Thioacetamide results in increased expression of TBC1D30 mRNA | CTD | PMID:23411599 | TBC1D30 | Human | titanium dioxide | decreases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | titanium dioxide results in decreased expression of TBC1D30 mRNA | CTD | PMID:23557971 | TBC1D30 | Human | titanium dioxide | decreases methylation | ISO | Tbc1d30 (Mus musculus) | 6480464 | titanium dioxide results in decreased methylation of TBC1D30 gene | CTD | PMID:35295148 | TBC1D30 | Human | trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of TBC1D30 mRNA | CTD | PMID:24935251 | TBC1D30 | Human | trichostatin A | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA | CTD | PMID:27188386 | TBC1D30 | Human | trichostatin A | decreases expression | EXP | | 6480464 | trichostatin A results in decreased expression of TBC1D30 mRNA | CTD | PMID:24935251 and PMID:26272509 | TBC1D30 | Human | triphenyl phosphate | affects expression | EXP | | 6480464 | triphenyl phosphate affects the expression of TBC1D30 mRNA | CTD | PMID:37042841 | TBC1D30 | Human | triptonide | increases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | triptonide results in increased expression of TBC1D30 mRNA | CTD | PMID:33045310 | TBC1D30 | Human | troglitazone | decreases expression | ISO | Tbc1d30 (Mus musculus) | 6480464 | troglitazone results in decreased expression of TBC1D30 mRNA | CTD | PMID:28973697 | TBC1D30 | Human | urethane | decreases expression | EXP | | 6480464 | Urethane results in decreased expression of TBC1D30 mRNA | CTD | PMID:28818685 | TBC1D30 | Human | valproic acid | increases expression | EXP | | 6480464 | Valproic Acid results in increased expression of TBC1D30 mRNA | CTD | PMID:24935251 | TBC1D30 | Human | valproic acid | affects expression | EXP | | 6480464 | Valproic Acid affects the expression of TBC1D30 mRNA | CTD | PMID:25979313 | TBC1D30 | Human | valproic acid | decreases expression | EXP | | 6480464 | Valproic Acid results in decreased expression of TBC1D30 mRNA | CTD | PMID:23179753 more ... | TBC1D30 | Human | valproic acid | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA | CTD | PMID:27188386 | TBC1D30 | Human | vorinostat | decreases expression | EXP | | 6480464 | vorinostat results in decreased expression of TBC1D30 mRNA | CTD | PMID:26272509 | TBC1D30 | Human | vorinostat | multiple interactions | EXP | | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TBC1D30 mRNA | CTD | PMID:27188386 | |